전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,132 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Dual Specificity CD38 and bcma CAR-T Cells (Dual Specificity CD38 and bcma CAR-T Cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleEssen BiotechPhase 2

Dual-Target Antigen-Selected CAR-NK (Dual-Target Antigen-Selected CAR-NK)

Cancer; Breast Cancer · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Advanced Solid Tumor · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting VEGFR1/PD-L1 CAR-T cells (Dual-targeting VEGFR1/PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

EB-CAR30-NK (EB-CAR30-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-CAR5-NK (EB-CAR5-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-CARMSLN-NK (EB-CARMSLN-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DUO-CAR-NK-CEA/GCC (EB-DUO-CAR-NK-CEA/GCC)

Colorectal Cancer; Metastatic Colorectal Adenocarcinoma · CEA

#CEA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-G3B7-NK dual-target CAR-NK cells (EB-G3B7-NK dual-target CAR-NK cells)

Advanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer · Advanced Hepatocellular Carcinoma (HCC)

#AdvancedHepatocellularCarcinomaH#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-MF-CAR-NK-01 (EB-MF-CAR-NK-01)

Malignant Pleural Mesotheliomas · Malignant Pleural Mesotheliomas

#MalignantPleuralMesotheliomas#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting

37 / 57 pages

← PreviousNext →